I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Core Insights - I-Mab announced that an abstract related to updated data from the Phase 1 study of givastomig has been accepted for presentation at the AACR-NCI-EORTC conference in Boston from October 22-26, 2025 [1][2] Group 1: Givastomig Development - Givastomig is a bispecific antibody targeting Claudin 18.2-positive tumor cells, designed to activate T cells through the 4-1BB signaling pathway in the tumor microenvironment [4][6] - The drug is being developed for first-line metastatic gastric cancers and other Claudin 18.2-positive gastrointestinal tumors, with promising anti-tumor activity observed in Phase 1 trials [4][6] - I-Mab is collaborating with ABL Bio for the development of givastomig, sharing worldwide rights excluding Greater China and South Korea [5] Group 2: Conference Presentation Details - The presentation at the conference will cover updated safety, efficacy, and biomarker analysis from the Phase I study of givastomig in Claudin 18.2 positive advanced gastroesophageal carcinoma [3] - The session is scheduled for October 23, 2025, from 6:20 to 6:35 PM ET at the Hynes Convention Center, with Dr. Samuel J. Klempner as the speaker [3]